Memo To File: FDA Managers Rebut Rogue Reviewer
This article was originally published in RPM Report
Here is a May 14 memo “to the file” signed by ODE I Director Ellis Unger, Deputy Director Robert Temple and Cardio-Renal Drug Products Division Director Norman Stockbridge, responding to the “unsolicited” reviews of Avandia submitted by cardio-renal division reviewer Thomas Marciniak. It was included in the briefing documents provided to the FDA advisory committee ahead of a June 5-6 meeting.
You may also be interested in...
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.
A $16bn provision to increase rebates in the US Medicaid program is a surprise inclusion in the COVID relief package moving through Congress. It looks like an uphill fight for industry to stop it from happening.
Latest Oncology Center of Excellence initiative is officially a CME effort designed to encourage practitioners to make full use of the information in the approved drug labeling. It is also a surprisingly effective way to explain drug approvals in a flattering light for regulators and sponsors.